1)Wang T, et al : Arachidonic acid metabolism and kidney inflammation. Int J Mol Sci 20 : 3683, 2019
2)Rucker D, et al : Physiology, thromboxane A2. StatPearls, Treasure Island, USA, 2022
3)中澤政之,他 : TX合成阻害薬オザグレルの開発研究.薬誌114 : 911-933,1994
4)Zhang J, et al : Ozagrel for acute ischemic stroke : a meta-analysis of data from randomized controlled trials. Neurol Res 34 : 346-353, 2012
5)町田和也,他 : トロンボキサンA2合成酵素阻害薬.日本臨床 54 : 3034-3039, 1996
6)Valdes G, et al : Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol 7 : 79, 2009
7)Satoh K, et al : Role of prostaglandins in pregnancy-induced hypertension. Am J Kidney Dis 17 : 133-138, 1991
8)Majed BH, et al : Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64 : 540-582, 2012
9)Seki H, et al : Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens Pregnancy 18 : 157-164, 1999
10)Chappell DL, et al : Development and validation of a LC/MS/MS method for 6-keto PGF1alpha, a metabolite of prostacyclin(PGI2). J Pharm Biomed Anal 56 : 600-603, 2011
11)Patrono C, et al : Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77 : 590-594, 1986
12)Nishida H, et al : New fetal growth curves for Japanese. Acta Paediatr Scand Suppl 319 : 62-67, 1985
13)Masotti G, et al : Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 2 : 1213-1217, 1979
14)Jin L, et al : Effects of six types of aspirin combination medications for treatment of acute cerebral infarction in China : a network meta-analysis. J Clin Pharm Ther 44 : 91-101, 2019